CL2022002067A1 - Composición para prevenir o tratar enfermedades pulmonares que comprende proteína 1 de unión de hialuronano - Google Patents
Composición para prevenir o tratar enfermedades pulmonares que comprende proteína 1 de unión de hialuronanoInfo
- Publication number
- CL2022002067A1 CL2022002067A1 CL2022002067A CL2022002067A CL2022002067A1 CL 2022002067 A1 CL2022002067 A1 CL 2022002067A1 CL 2022002067 A CL2022002067 A CL 2022002067A CL 2022002067 A CL2022002067 A CL 2022002067A CL 2022002067 A1 CL2022002067 A1 CL 2022002067A1
- Authority
- CL
- Chile
- Prior art keywords
- hapln1
- composition
- lung diseases
- binding protein
- protein
- Prior art date
Links
- 208000019693 Lung disease Diseases 0.000 title abstract 3
- 102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 title 1
- 101000740725 Homo sapiens Complement component 1 Q subcomponent-binding protein, mitochondrial Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 2
- 229940099552 hyaluronan Drugs 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 102000028619 proteoglycan binding proteins Human genes 0.000 abstract 2
- 108091009335 proteoglycan binding proteins Proteins 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102000016942 Elastin Human genes 0.000 abstract 1
- 108010014258 Elastin Proteins 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000008382 alveolar damage Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229920002549 elastin Polymers 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Se proporcionan una proteína 1 de unión de hialuronano y proteoglucano (HAPLN1) recombinante y una composición para prevenir o tratar enfermedades pulmonares, comprendiendo la composición al menos uno seleccionado del grupo que consiste en proteína HAPLN1 (proteína 1 de unión de hialuronano y proteoglucano), un gen que codifica la proteína HAPLN1 y un agente eficaz para potenciar la expresión o activar las funciones de la proteína o el gen HAPLN1 como principio activo. La HAPLN1 recombinante de acuerdo con la presente divulgación puede tener efectos superiores de mejora del daño alveolar provocado por el envejecimiento o la reducción de elastina y, por tanto, puede prevenir o tratar de manera eficaz enfermedades pulmonares, tales como bronquitis crónica, asma, enfisema y enfermedad pulmonar obstructiva crónica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200012742A KR102166453B1 (ko) | 2020-02-03 | 2020-02-03 | Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002067A1 true CL2022002067A1 (es) | 2023-01-20 |
Family
ID=72882981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002067A CL2022002067A1 (es) | 2020-02-03 | 2022-08-01 | Composición para prevenir o tratar enfermedades pulmonares que comprende proteína 1 de unión de hialuronano |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220305077A1 (es) |
| EP (1) | EP3887525B1 (es) |
| JP (1) | JP7329877B2 (es) |
| KR (1) | KR102166453B1 (es) |
| CN (1) | CN115427576A (es) |
| AR (1) | AR121243A1 (es) |
| AU (1) | AU2021216358A1 (es) |
| BR (1) | BR112022015361A2 (es) |
| CA (1) | CA3166146A1 (es) |
| CL (1) | CL2022002067A1 (es) |
| CO (1) | CO2022011135A2 (es) |
| ES (1) | ES2964715T3 (es) |
| IL (1) | IL294952A (es) |
| MX (1) | MX2022009544A (es) |
| PE (1) | PE20221663A1 (es) |
| TW (1) | TWI792171B (es) |
| WO (1) | WO2021158000A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102284800B1 (ko) | 2020-12-30 | 2021-08-03 | 주식회사 하플사이언스 | 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법 |
| KR20220161730A (ko) * | 2021-05-31 | 2022-12-07 | 중앙대학교 산학협력단 | Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785969B1 (ko) | 2004-05-12 | 2007-12-14 | 동아제약주식회사 | Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
| EA030440B1 (ru) * | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
| EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| ES2846789T3 (es) * | 2012-07-11 | 2021-07-29 | Tissuetech Inc | Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos |
| KR101897340B1 (ko) * | 2015-09-09 | 2018-09-13 | 중앙대학교 산학협력단 | Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물 |
| AU2017403257B2 (en) * | 2017-03-06 | 2021-09-30 | Haplnscience inc. | Composition for skin aging measurement, prevention, or alleviation, using HAPLN1 |
-
2020
- 2020-02-03 KR KR1020200012742A patent/KR102166453B1/ko active IP Right Grant
-
2021
- 2021-02-01 AR ARP210100261A patent/AR121243A1/es unknown
- 2021-02-02 AU AU2021216358A patent/AU2021216358A1/en active Pending
- 2021-02-02 CA CA3166146A patent/CA3166146A1/en active Pending
- 2021-02-02 US US17/287,443 patent/US20220305077A1/en active Pending
- 2021-02-02 BR BR112022015361A patent/BR112022015361A2/pt unknown
- 2021-02-02 MX MX2022009544A patent/MX2022009544A/es unknown
- 2021-02-02 CN CN202180001405.5A patent/CN115427576A/zh active Pending
- 2021-02-02 PE PE2022001520A patent/PE20221663A1/es unknown
- 2021-02-02 EP EP21717303.8A patent/EP3887525B1/en active Active
- 2021-02-02 JP JP2021521505A patent/JP7329877B2/ja active Active
- 2021-02-02 WO PCT/KR2021/001374 patent/WO2021158000A1/en unknown
- 2021-02-02 ES ES21717303T patent/ES2964715T3/es active Active
- 2021-02-02 IL IL294952A patent/IL294952A/en unknown
- 2021-02-03 TW TW110104089A patent/TWI792171B/zh active
-
2022
- 2022-08-01 CL CL2022002067A patent/CL2022002067A1/es unknown
- 2022-08-05 CO CONC2022/0011135A patent/CO2022011135A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021216358A1 (en) | 2022-09-01 |
| EP3887525C0 (en) | 2023-08-23 |
| JP2022524899A (ja) | 2022-05-11 |
| MX2022009544A (es) | 2022-08-25 |
| CA3166146A1 (en) | 2021-08-12 |
| CN115427576A (zh) | 2022-12-02 |
| EP3887525A1 (en) | 2021-10-06 |
| CO2022011135A2 (es) | 2022-08-30 |
| TW202130360A (zh) | 2021-08-16 |
| EP3887525B1 (en) | 2023-08-23 |
| WO2021158000A1 (en) | 2021-08-12 |
| KR102166453B1 (ko) | 2020-10-15 |
| US20220305077A1 (en) | 2022-09-29 |
| EP3887525A4 (en) | 2022-06-22 |
| IL294952A (en) | 2022-09-01 |
| AR121243A1 (es) | 2022-05-04 |
| PE20221663A1 (es) | 2022-10-26 |
| TWI792171B (zh) | 2023-02-11 |
| JP7329877B2 (ja) | 2023-08-21 |
| BR112022015361A2 (pt) | 2022-09-20 |
| ES2964715T3 (es) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002067A1 (es) | Composición para prevenir o tratar enfermedades pulmonares que comprende proteína 1 de unión de hialuronano | |
| BR112012026730A2 (pt) | vetor viral adeno-associado recombinante, pluralidade de partículas virais infecciosas, células hospedeira de mamífero, kit, uso de composição, métodos para prevenir, tratar ou melhorar doença, disfunção, distúrbio, deficiência ou condição anormal em manífero de um ou mais sintomas dos mesmos, para prover quantidade terapeuticamente eficaz de peptídeo, polipeptídeo ou proteína de guanilato ciclase a mamífero biologicamente ativo em necessidade da mesma, para aumentar o nível de proteína retgc1 biologicamente em um ou mais células retinais de mamífero e para tratar ou melhorar um ou mais sintomas de distrofia retinal em mamífero | |
| BR112014029442A2 (pt) | composições antimucosas à base de xilitol e métodos e composições relacionados | |
| BR112017012327A2 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| EP3536794A3 (de) | Peptide mit spezifität für die lunge | |
| ECSP088430A (es) | Diarilurea para el tratamiento de hipertensión pulmonar | |
| AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
| BRPI0511367A (pt) | uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo | |
| AR118850A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
| WO2008073395A3 (en) | Compositions and methods for cardiac tissue protection and regeneration | |
| MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
| WO2010028173A3 (en) | Method of treating atrial fibrillation | |
| BR112014003071A2 (pt) | tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical | |
| BR112018001533A2 (pt) | método de redução da necessidade de cirurgia em pacientes sofrendo da hiperplasia benigna da próstata | |
| BR112012027080A2 (pt) | composições orgânicas para tratar doenças relacionadas a beta - ena | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
| CL2020000597A1 (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas. | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| BR112021019845A2 (pt) | Composições de vírus inativado e formulações de vacina contra zika | |
| BR112014030777A2 (pt) | método e composição para aliviar sintomas de tumor | |
| CO2023014900A2 (es) | Tratamiento génico para miocardiopatía arritmogénica del ventrículo derecho | |
| PH12017502145A1 (en) | Composition and uses thereof | |
| MX2021003123A (es) | Isomeros rotomericos de 4-alquil-5-heteroaril-3h-1,2-ditiol-3-tion as. |